REGENERON PHARMACEUTICALS, INC. Insider Trading for April 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. for April 2020.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 18,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 6,622 | 392,022 | 23,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 29,933 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 573.59 | 577 | 330,961 | 14,438 | 15 K to 14.4 K (-3.84 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 572.94 | 61 | 34,949 | 15,015 | 15.1 K to 15 K (-0.40 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 571.65 | 112 | 64,025 | 15,076 | 15.2 K to 15.1 K (-0.74 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 570.27 | 125 | 71,284 | 15,188 | 15.3 K to 15.2 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 569.41 | 234 | 133,242 | 15,313 | 15.5 K to 15.3 K (-1.51 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 567.30 | 669 | 379,524 | 15,547 | 16.2 K to 15.5 K (-4.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 566.44 | 1,189 | 673,497 | 16,216 | 17.4 K to 16.2 K (-6.83 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.60 | 1,468 | 830,301 | 17,405 | 18.9 K to 17.4 K (-7.78 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.74 | 377 | 212,907 | 18,873 | 19.3 K to 18.9 K (-1.96 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.58 | 416 | 234,449 | 19,250 | 19.7 K to 19.3 K (-2.12 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.71 | 21 | 11,817 | 19,666 | 19.7 K to 19.7 K (-0.11 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.57 | 51 | 28,640 | 19,687 | 19.7 K to 19.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 18,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 2,720 | 1,511,830 | 19,738 | 22.5 K to 19.7 K (-12.11 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 6,622 | 392,022 | 23,311 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 22,458 | 17.5 K to 22.5 K (+28.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 29,933 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 3,602 | 2,002,064 | 17,458 | 21.1 K to 17.5 K (-17.10 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 573.59 | 577 | 330,961 | 14,438 | 15 K to 14.4 K (-3.84 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 6,622 | 392,022 | 21,060 | 14.4 K to 21.1 K (+45.87 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 572.94 | 61 | 34,949 | 15,015 | 15.1 K to 15 K (-0.40 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.92 | 94 | 53,196 | 14,438 | 14.5 K to 14.4 K (-0.65 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 571.65 | 112 | 64,025 | 15,076 | 15.2 K to 15.1 K (-0.74 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.19 | 93 | 52,470 | 14,532 | 14.6 K to 14.5 K (-0.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 570.27 | 125 | 71,284 | 15,188 | 15.3 K to 15.2 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.39 | 171 | 96,340 | 14,625 | 14.8 K to 14.6 K (-1.16 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 569.41 | 234 | 133,242 | 15,313 | 15.5 K to 15.3 K (-1.51 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.56 | 191 | 107,449 | 14,796 | 15 K to 14.8 K (-1.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 567.30 | 669 | 379,524 | 15,547 | 16.2 K to 15.5 K (-4.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.76 | 63 | 35,391 | 14,987 | 15.1 K to 15 K (-0.42 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 566.44 | 1,189 | 673,497 | 16,216 | 17.4 K to 16.2 K (-6.83 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 560.38 | 163 | 91,342 | 15,050 | 15.2 K to 15.1 K (-1.07 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.60 | 1,468 | 830,301 | 17,405 | 18.9 K to 17.4 K (-7.78 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 559.79 | 285 | 159,540 | 15,213 | 15.5 K to 15.2 K (-1.84 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.74 | 377 | 212,907 | 18,873 | 19.3 K to 18.9 K (-1.96 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 558.55 | 293 | 163,655 | 15,498 | 15.8 K to 15.5 K (-1.86 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.58 | 416 | 234,449 | 19,250 | 19.7 K to 19.3 K (-2.12 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 557.40 | 93 | 51,838 | 15,791 | 15.9 K to 15.8 K (-0.59 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.71 | 21 | 11,817 | 19,666 | 19.7 K to 19.7 K (-0.11 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 556.51 | 198 | 110,189 | 15,884 | 16.1 K to 15.9 K (-1.23 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.57 | 51 | 28,640 | 19,687 | 19.7 K to 19.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 555.10 | 114 | 63,281 | 16,082 | 16.2 K to 16.1 K (-0.70 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 2,720 | 1,511,830 | 19,738 | 22.5 K to 19.7 K (-12.11 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 552.85 | 104 | 57,496 | 16,196 | 16.3 K to 16.2 K (-0.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 22,458 | 17.5 K to 22.5 K (+28.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 550.00 | 6 | 3,300 | 16,300 | 16.3 K to 16.3 K (-0.04 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 555.82 | 3,602 | 2,002,064 | 17,458 | 21.1 K to 17.5 K (-17.10 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 549.24 | 100 | 54,924 | 16,306 | 16.4 K to 16.3 K (-0.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 6,622 | 392,022 | 21,060 | 14.4 K to 21.1 K (+45.87 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 548.27 | 99 | 54,279 | 16,406 | 16.5 K to 16.4 K (-0.60 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 565.92 | 94 | 53,196 | 14,438 | 14.5 K to 14.4 K (-0.65 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 547.00 | 100 | 54,700 | 16,505 | 16.6 K to 16.5 K (-0.60 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 564.19 | 93 | 52,470 | 14,532 | 14.6 K to 14.5 K (-0.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 542.31 | 5 | 2,712 | 16,605 | 16.6 K to 16.6 K (-0.03 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 563.39 | 171 | 96,340 | 14,625 | 14.8 K to 14.6 K (-1.16 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 541.94 | 95 | 51,484 | 16,610 | 16.7 K to 16.6 K (-0.57 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 562.56 | 191 | 107,449 | 14,796 | 15 K to 14.8 K (-1.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 529.79 | 2,733 | 1,447,916 | 16,705 | 19.4 K to 16.7 K (-14.06 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 561.76 | 63 | 35,391 | 14,987 | 15.1 K to 15 K (-0.42 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 560.38 | 163 | 91,342 | 15,050 | 15.2 K to 15.1 K (-1.07 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 559.79 | 285 | 159,540 | 15,213 | 15.5 K to 15.2 K (-1.84 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 558.55 | 293 | 163,655 | 15,498 | 15.8 K to 15.5 K (-1.86 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 557.40 | 93 | 51,838 | 15,791 | 15.9 K to 15.8 K (-0.59 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 556.51 | 198 | 110,189 | 15,884 | 16.1 K to 15.9 K (-1.23 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 555.10 | 114 | 63,281 | 16,082 | 16.2 K to 16.1 K (-0.70 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 552.85 | 104 | 57,496 | 16,196 | 16.3 K to 16.2 K (-0.64 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 550.00 | 6 | 3,300 | 16,300 | 16.3 K to 16.3 K (-0.04 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 549.24 | 100 | 54,924 | 16,306 | 16.4 K to 16.3 K (-0.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 548.27 | 99 | 54,279 | 16,406 | 16.5 K to 16.4 K (-0.60 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 547.00 | 100 | 54,700 | 16,505 | 16.6 K to 16.5 K (-0.60 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 542.31 | 5 | 2,712 | 16,605 | 16.6 K to 16.6 K (-0.03 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 541.94 | 95 | 51,484 | 16,610 | 16.7 K to 16.6 K (-0.57 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 529.79 | 2,733 | 1,447,916 | 16,705 | 19.4 K to 16.7 K (-14.06 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 34,933 | |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 525.30 | 6 | 3,152 | 14,438 | 14.4 K to 14.4 K (-0.04 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 524.99 | 106 | 55,649 | 14,444 | 14.6 K to 14.4 K (-0.73 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 521.05 | 113 | 58,879 | 14,550 | 14.7 K to 14.6 K (-0.77 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 520.45 | 220 | 114,499 | 14,663 | 14.9 K to 14.7 K (-1.48 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 519.43 | 286 | 148,557 | 14,883 | 15.2 K to 14.9 K (-1.89 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 518.25 | 499 | 258,607 | 15,169 | 15.7 K to 15.2 K (-3.18 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 517.40 | 266 | 137,628 | 15,668 | 15.9 K to 15.7 K (-1.67 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 516.81 | 260 | 134,371 | 15,934 | 16.2 K to 15.9 K (-1.61 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 515.70 | 414 | 213,500 | 16,194 | 16.6 K to 16.2 K (-2.49 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 514.63 | 92 | 47,346 | 16,608 | 16.7 K to 16.6 K (-0.55 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 521.45 | 2,738 | 1,427,730 | 16,700 | 19.4 K to 16.7 K (-14.09 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 35,500 | |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 525.30 | 2 | 1,051 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 520.36 | 130 | 67,647 | 24,375 | 24.5 K to 24.4 K (-0.53 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 519.58 | 76 | 39,488 | 24,505 | 24.6 K to 24.5 K (-0.31 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 518.31 | 287 | 148,755 | 24,581 | 24.9 K to 24.6 K (-1.15 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.84 | 304 | 157,423 | 24,868 | 25.2 K to 24.9 K (-1.21 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 516.89 | 54 | 27,912 | 25,172 | 25.2 K to 25.2 K (-0.21 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 521.45 | 2,647 | 1,380,278 | 25,226 | 27.9 K to 25.2 K (-9.50 %) |
Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 52.03 | 13,079 | 680,500 | 25,000 | |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 524.26 | 357 | 187,161 | 11,380 | 11.7 K to 11.4 K (-3.04 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 522.37 | 758 | 395,956 | 11,737 | 12.5 K to 11.7 K (-6.07 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 521.32 | 1,595 | 831,505 | 12,495 | 14.1 K to 12.5 K (-11.32 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 520.43 | 2,096 | 1,090,821 | 14,090 | 16.2 K to 14.1 K (-12.95 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 519.85 | 422 | 219,377 | 16,186 | 16.6 K to 16.2 K (-2.54 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 518.54 | 267 | 138,450 | 16,608 | 16.9 K to 16.6 K (-1.58 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 517.99 | 2 | 1,036 | 16,875 | 16.9 K to 16.9 K (-0.01 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 511.56 | 7,582 | 3,878,648 | 16,877 | 24.5 K to 16.9 K (-31.00 %) |
Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Buy | M | 52.03 | 13,079 | 680,500 | 24,459 | 11.4 K to 24.5 K (+114.93 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 39,000 | |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.71 | 46 | 23,815 | 24,373 | 24.4 K to 24.4 K (-0.19 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 512.58 | 31 | 15,890 | 24,419 | 24.5 K to 24.4 K (-0.13 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 511.59 | 156 | 79,808 | 24,450 | 24.6 K to 24.5 K (-0.63 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 510.43 | 143 | 72,991 | 24,606 | 24.7 K to 24.6 K (-0.58 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 509.45 | 170 | 86,607 | 24,749 | 24.9 K to 24.7 K (-0.68 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 508.54 | 115 | 58,482 | 24,919 | 25 K to 24.9 K (-0.46 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 507.45 | 30 | 15,224 | 25,034 | 25.1 K to 25 K (-0.12 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 506.24 | 38 | 19,237 | 25,064 | 25.1 K to 25.1 K (-0.15 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 505.60 | 99 | 50,054 | 25,102 | 25.2 K to 25.1 K (-0.39 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 508.25 | 2,672 | 1,358,044 | 25,201 | 27.9 K to 25.2 K (-9.59 %) |
Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 42,500 | |
Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 502.81 | 2 | 1,006 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.50 | 694 | 345,265 | 24,375 | 25.1 K to 24.4 K (-2.77 %) |
Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 499.95 | 2,304 | 1,151,885 | 25,069 | 27.4 K to 25.1 K (-8.42 %) |
Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 27,373 | 24.4 K to 27.4 K (+12.31 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 39,933 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 44,933 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 49,933 | |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 497.32 | 100 | 49,732 | 14,438 | 14.5 K to 14.4 K (-0.69 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 496.50 | 210 | 104,265 | 14,538 | 14.7 K to 14.5 K (-1.42 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 495.19 | 321 | 158,956 | 14,748 | 15.1 K to 14.7 K (-2.13 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 494.36 | 111 | 54,874 | 15,069 | 15.2 K to 15.1 K (-0.73 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 493.35 | 652 | 321,664 | 15,180 | 15.8 K to 15.2 K (-4.12 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 492.62 | 521 | 256,655 | 15,832 | 16.4 K to 15.8 K (-3.19 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 491.42 | 450 | 221,139 | 16,353 | 16.8 K to 16.4 K (-2.68 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 490.32 | 484 | 237,315 | 16,803 | 17.3 K to 16.8 K (-2.80 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 489.72 | 734 | 359,454 | 17,287 | 18 K to 17.3 K (-4.07 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 488.26 | 1,626 | 793,911 | 18,021 | 19.6 K to 18 K (-8.28 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 487.71 | 470 | 229,224 | 19,647 | 20.1 K to 19.6 K (-2.34 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 486.61 | 485 | 236,006 | 20,117 | 20.6 K to 20.1 K (-2.35 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 485.65 | 441 | 214,172 | 20,602 | 21 K to 20.6 K (-2.10 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 484.58 | 192 | 93,039 | 21,043 | 21.2 K to 21 K (-0.90 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,689 | 1,312,824 | 21,235 | 23.9 K to 21.2 K (-11.24 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 23,924 | 18.9 K to 23.9 K (+26.42 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,757 | 1,346,023 | 18,924 | 21.7 K to 18.9 K (-12.72 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 21,681 | 16.7 K to 21.7 K (+29.97 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,757 | 1,346,023 | 16,681 | 19.4 K to 16.7 K (-14.18 %) |
Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 495.66 | 1 | 496 | 28,943 | 28.9 K to 28.9 K (0.00 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 493.35 | 1 | 493 | 28,944 | 28.9 K to 28.9 K (0.00 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 492.71 | 3 | 1,478 | 28,945 | 28.9 K to 28.9 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 491.13 | 2 | 982 | 28,948 | 29 K to 28.9 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 490.35 | 1 | 490 | 28,950 | 29 K to 29 K (0.00 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 489.56 | 5 | 2,448 | 28,951 | 29 K to 29 K (-0.02 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 488.62 | 10 | 4,886 | 28,956 | 29 K to 29 K (-0.03 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 487.54 | 1 | 488 | 28,966 | 29 K to 29 K (0.00 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 486.53 | 4 | 1,946 | 28,967 | 29 K to 29 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 485.65 | 3 | 1,457 | 28,971 | 29 K to 29 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 484.54 | 8 | 3,876 | 28,974 | 29 K to 29 K (-0.03 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 483.49 | 11 | 5,318 | 28,982 | 29 K to 29 K (-0.04 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 482.43 | 14 | 6,754 | 28,993 | 29 K to 29 K (-0.05 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 481.34 | 4 | 1,925 | 29,007 | 29 K to 29 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 480.55 | 8 | 3,844 | 29,011 | 29 K to 29 K (-0.03 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 479.60 | 18 | 8,633 | 29,019 | 29 K to 29 K (-0.06 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 478.45 | 4 | 1,914 | 29,037 | 29 K to 29 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 477.58 | 2 | 955 | 29,041 | 29 K to 29 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 469.49 | 4 | 1,878 | 29,043 | 29 K to 29 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 468.14 | 24 | 11,235 | 29,047 | 29.1 K to 29 K (-0.08 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 467.51 | 19 | 8,883 | 29,071 | 29.1 K to 29.1 K (-0.07 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 466.60 | 23 | 10,732 | 29,090 | 29.1 K to 29.1 K (-0.08 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 465.35 | 16 | 7,446 | 29,113 | 29.1 K to 29.1 K (-0.05 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 464.49 | 9 | 4,180 | 29,129 | 29.1 K to 29.1 K (-0.03 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 463.16 | 3 | 1,389 | 29,138 | 29.1 K to 29.1 K (-0.01 %) |
Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 462.80 | 2 | 926 | 29,141 | 29.1 K to 29.1 K (-0.01 %) |